DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data esta ...

We expect our cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement ...

Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the third quarter of 2024 and provided a business update. In a separate press release issued earlier ...

Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Meta to Offer 'Less Personalized Ads' in Concession to EU The Facebook and Instagram ... Schrödinger enters collaboration pact with Novartis worth up to $2.5 billion Schrödinger will receive $150 ...

Sandoz is offering a generic paclitaxel formulation, which is the first FDA-approved ANDA to BioScience’s Abraxane for ...

“Bruce had a brilliant career in both academia and industry and left an indelible mark on the Alzheimer’s disease drug development landscape,” noted Robert Vassar, Northwestern University, Chicago ...

The daylong leadership conference touched on numerous topics relevant to medical marketers, pharma executives and media ...

With full confidence in China, where Novartis recorded 17 percent growth last year, one of the fastest among all major ...

ZURICH (Reuters) - Novartis (SIX: NOVN) expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...